MedPath

Novan, Inc.

Novan, Inc. logo
🇺🇸United States
Ownership
Public
Established
2008-01-01
Employees
89
Market Cap
-
Website
http://www.novan.com

Clinical Trials

21

Active:0
Completed:21

Trial Phases

3 Phases

Phase 1:10
Phase 2:5
Phase 3:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (47.6%)
Phase 3
6 (28.6%)
Phase 2
5 (23.8%)

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study

Phase 3
Completed
Conditions
Molluscum Contagiosum
Interventions
Drug: SB206 10.3% berdazimer
Drug: vehicle gel
First Posted Date
2020-09-02
Last Posted Date
2023-01-26
Lead Sponsor
Novan, Inc.
Target Recruit Count
891
Registration Number
NCT04535531
Locations
🇺🇸

Site #312, Glendale, Arizona, United States

🇺🇸

Site #101, Hot Springs, Arkansas, United States

🇺🇸

Site #272, Rogers, Arkansas, United States

and more 52 locations

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

Phase 3
Completed
Conditions
Molluscum Contagiosum
Interventions
Drug: SB206 12%
Drug: Placebo
First Posted Date
2019-04-25
Last Posted Date
2023-03-23
Lead Sponsor
Novan, Inc.
Target Recruit Count
355
Registration Number
NCT03927703
Locations
🇺🇸

Site #266, Scottsdale, Arizona, United States

🇺🇸

Site #101, Hot Springs, Arkansas, United States

🇺🇸

Site #282, Beverly Hills, California, United States

and more 24 locations

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Phase 3
Completed
Conditions
Molluscum Contagiosum
Interventions
Drug: Placebo
Drug: SB206 12%
First Posted Date
2019-04-25
Last Posted Date
2022-12-27
Lead Sponsor
Novan, Inc.
Target Recruit Count
352
Registration Number
NCT03927716
Locations
🇺🇸

Site #218, Mobile, Alabama, United States

🇺🇸

Site #312, Glendale, Arizona, United States

🇺🇸

Site #298, Little Rock, Arkansas, United States

and more 32 locations

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

Phase 1
Completed
Conditions
Psoriasis
Interventions
Drug: SB414 6%
Drug: Vehicle
First Posted Date
2018-02-26
Last Posted Date
2018-03-27
Lead Sponsor
Novan, Inc.
Target Recruit Count
36
Registration Number
NCT03445013
Locations
🇺🇸

Novella Site# 247, Boise, Idaho, United States

🇺🇸

Novella Site# 183, Austin, Texas, United States

🇺🇸

Novella Site# 249, College Station, Texas, United States

and more 1 locations

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

Phase 2
Completed
Conditions
Molluscum Contagiosum
Interventions
Drug: SB206 8%
Drug: SB206 12%
Drug: Placebo
Drug: SB206 4%
First Posted Date
2018-02-19
Last Posted Date
2023-05-06
Lead Sponsor
Novan, Inc.
Target Recruit Count
256
Registration Number
NCT03436615
Locations
🇺🇸

Premier Site# 266, Scottsdale, Arizona, United States

🇺🇸

Premier Site# 260, Santa Ana, California, United States

🇺🇸

Premier Site# 257, Thornton, Colorado, United States

and more 15 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.